Soleymanlou, Nima

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,329

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology

Cardiovascular Health and Disease PreventionDiabetes Treatment and Management

Cited by 470

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 363

Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, placebo-controlled trial (EASE-1)

Famulla, S., Pieber, T. R., Eilbracht, J., Neubacher, D., Soleymanlou, N., Woerle, H. J., Broedl, U. C., & Kaspers, S. (2017) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 53

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

van Bommel, E. J. M., Lytvyn, Y., Perkins, B. A., Soleymanlou, N., Fagan, N. M., Koitka-Weber, A., Joles, J. A., Cherney, D. Z. I., & van Raalte, D. H. (2020) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 47